NASDAQ:KMPH

KemPharm Stock Forecast, Price & News

$0.54

+0.02 (+3.85 %)

(As of 10/23/2020 12:00 AM ET)

Add

Compare

Today's Range

$0.52

Now: $0.54▼

$0.56

50-Day Range

$0.50

MA: $0.66▼

$0.74

52-Week Range

$0.12

Now: $0.54▼

$0.93

Volume201,787 shs

Average Volume1.87 million shs

Market Capitalization$39.15 million

P/E RatioN/A

Dividend YieldN/A

Beta1.6

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. The company has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. KemPharm, Inc. was founded in 2006 and is headquartered in Celebration, Florida.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
KemPharm has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.50, KemPharm has a forecasted upside of 177.8% from its current price of $0.54.
Amount of Analyst Coverage
KemPharm has only been the subject of 1 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
KemPharm has received 340 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
KemPharm has received 235 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
KemPharm has received 59.13% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote “Outperform” if you believe KMPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
KemPharm does not currently pay a dividend.
Dividend Growth
KemPharm does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, KemPharm insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,640.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 14.90% of the stock of KemPharm is held by insiders.
Percentage Held by Institutions
Only 14.15% of the stock of KemPharm is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for KemPharm are expected to grow in the coming year, from ($0.16) to $0.02 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of KemPharm is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of KemPharm is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

2.03 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KMPH

Previous Symbol

CUSIPN/A

CIK1434647

Webwww.kempharm.com

Phone321-939-3416

Employees33

Debt

Debt-to-Equity RatioN/A

Current Ratio0.07

Quick Ratio0.07

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$12.84 million

Price / Sales3.05

Cash FlowN/A

Price / Cash FlowN/A

Book Value($1.04) per share

Price / Book-0.52

Profitability

EPS (Most Recent Fiscal Year)($0.88)

Net Income$-24,520,000.00

Net MarginsN/A

Return on EquityN/A

Return on Assets-163.41%

Miscellaneous

Outstanding Shares72,514,000

Market Cap$39.15 million

Next Earnings Date11/12/2020 (Estimated)

OptionableOptionable

$0.54

+0.02 (+3.85 %)

(As of 10/23/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive KMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter.

KemPharm (NASDAQ:KMPH) Frequently Asked Questions

How has KemPharm's stock price been impacted by Coronavirus (COVID-19)?

KemPharm's stock was trading at $0.2452 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KMPH shares have increased by 120.2% and is now trading at $0.5399.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of KemPharm?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for KemPharm.

When is KemPharm's next earnings date?

KemPharm is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for KemPharm.

How were KemPharm's earnings last quarter?

KemPharm Inc (NASDAQ:KMPH) announced its earnings results on Wednesday, August, 12th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $6.91 million during the quarter, compared to analyst estimates of $6.75 million.
View KemPharm's earnings history.

What price target have analysts set for KMPH?

1 Wall Street analysts have issued twelve-month price objectives for KemPharm's shares. Their forecasts range from $1.50 to $1.50. On average, they expect KemPharm's stock price to reach $1.50 in the next year. This suggests a possible upside of 177.8% from the stock's current price.
View analysts' price targets for KemPharm.

Who are some of KemPharm's key competitors?

Some companies that are related to KemPharm include GlycoMimetics (GLYC), Actinium Pharmaceuticals (ATNM), Galectin Therapeutics (GALT), AVEO Pharmaceuticals (AVEO), ContraFect (CFRX), Milestone Pharmaceuticals (MIST), BELLUS Health (BLU), Aptinyx (APTX), Checkpoint Therapeutics (CKPT), Exicure (XCUR), Ampio Pharmaceuticals (AMPE), Ampio Pharmaceuticals (AMPE), Lexicon Pharmaceuticals (LXRX), Sesen Bio (SESN) and Minerva Neurosciences (NERV).
View all competitors.

What other stocks do shareholders of KemPharm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KemPharm investors own include Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO), Aldeyra Therapeutics (ALDX), Exelixis (EXEL), BioCryst Pharmaceuticals (BCRX), Cara Therapeutics (CARA), DURECT (DRRX) and Paratek Pharmaceuticals (PRTK).

Who are KemPharm's key executives?

KemPharm's management team includes the following people:

Dr. Travis C. Mickle, Co-Founder, Chairman, Pres & CEO (Age 46)
Dr. Sven Guenther, Exec. VP of R&D (Age 47)
Mr. Gordon K. Johnson, Chief Bus. Officer (Age 67)
Ms. Christal M. M. Mickle, Co-Founder and VP of Operations & Product Devel. (Age 40)
Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 47)

When did KemPharm IPO?

(KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How do I buy shares of KemPharm?

Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is KemPharm's stock price today?

One share of KMPH stock can currently be purchased for approximately $0.54.

How big of a company is KemPharm?

KemPharm has a market capitalization of $39.15 million and generates $12.84 million in revenue each year. The specialty pharmaceutical company earns $-24,520,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. KemPharm employs 33 workers across the globe.

What is KemPharm's official website?

The official website for KemPharm is www.kempharm.com.

How can I contact KemPharm?

KemPharm's mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The specialty pharmaceutical company can be reached via phone at 321-939-3416 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings